Unión Europea - español - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - dihidrocloruro de sapropterina - fenilcetonurias - otros tracto alimentario y metabolismo de los productos, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

Unión Europea - español - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamida - neoplasmas prostáticos - terapia endocrina - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Unión Europea - español - EMA (European Medicines Agency)

taw pharma (ireland) limited - clorhidrato de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agentes antitrombóticos - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Unión Europea - español - EMA (European Medicines Agency)

norton healthcare ltd. - paclitaxel - sarcoma, kaposi; carcinoma, non-small-cell lung; ovarian neoplasms; breast neoplasms - agentes antineoplásicos - paxene está indicado para el tratamiento de pacientes con:• avanzadas relacionadas con el sida, el sarcoma de kaposi (sk-sida) en los que han fracasado antes de antraciclina liposomal terapia;• el carcinoma metastásico de mama (mbc) que no han podido, o no son candidatos para el estándar de la antraciclina que contiene la terapia;• carcinoma avanzado de ovario (aoc) o con enfermedad residual (> 1 cm) después de la laparotomía inicial, en combinación con cisplatino como tratamiento de primera línea;• el carcinoma metastásico de ovario (moc) después del fracaso de platino que contiene la terapia de combinación sin taxanos como tratamiento de segunda línea;• no de células pequeñas, carcinoma de pulmón no microcítico (cpnm) que no son candidatos para cirugía potencialmente curativa y/o terapia de radiación, en combinación con cisplatino. los datos de eficacia limitados apoyan esta indicación (ver sección 5.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mundipharma pharmaceuticals s.l. - morfina sulfato - comprimido de liberaciÓn prolongada - 10 mg - morfina sulfato 10 mg - morfina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mundipharma pharmaceuticals s.l. - morfina sulfato - comprimido de liberaciÓn prolongada - 100 mg - morfina sulfato 100 mg - morfina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mundipharma pharmaceuticals s.l. - morfina sulfato - comprimido de liberaciÓn prolongada - 15 mg - morfina sulfato 15 mg - morfina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mundipharma pharmaceuticals s.l. - morfina sulfato - comprimido de liberaciÓn prolongada - 200 mg - morfina sulfato 200 mg - morfina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mundipharma pharmaceuticals s.l. - morfina sulfato - comprimido de liberaciÓn prolongada - 30 mg - morfina sulfato 30 mg - morfina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mundipharma pharmaceuticals s.l. - morfina sulfato - comprimido de liberaciÓn prolongada - 5 mg - morfina sulfato 5 mg - morfina